https://spypharm.com/rss/category/pharmaceutical SpyPharm | Pharmaceutical News, Developments & Trends & : Pharmaceutical en Copyright 2023 Spypharm & All Rights Reserved. https://spypharm.com/almirall-completes-eu-regulatory-procedure-for-antifungal-jublia https://spypharm.com/almirall-completes-eu-regulatory-procedure-for-antifungal-jublia Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/the-growing-role-of-cdmos-in-the-circular-economy https://spypharm.com/the-growing-role-of-cdmos-in-the-circular-economy Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/parenteral-solutions-in-contract-manufacturing-for-the-pharmaceutical-industry https://spypharm.com/parenteral-solutions-in-contract-manufacturing-for-the-pharmaceutical-industry Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/hanmi-and-medic-ink-cancer-biomarker-collaboration-deal https://spypharm.com/hanmi-and-medic-ink-cancer-biomarker-collaboration-deal Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/bayer-applies-for-eu-approval-of-menopause-drug-elinzanetant https://spypharm.com/bayer-applies-for-eu-approval-of-menopause-drug-elinzanetant Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/digital-twins-a-new-path-to-personalised-medicine https://spypharm.com/digital-twins-a-new-path-to-personalised-medicine Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/the-science-of-viscous-drug-product-filling-pumps-pressure-and-process-optimization https://spypharm.com/the-science-of-viscous-drug-product-filling-pumps-pressure-and-process-optimization Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/lilly-touts-omvohs-superiority-over-jjs-stelara-in-crohns https://spypharm.com/lilly-touts-omvohs-superiority-over-jjs-stelara-in-crohns Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/transgenes-stock-drops-after-phase-ii-cancer-jab-trial-misses-primary-endpoint https://spypharm.com/transgenes-stock-drops-after-phase-ii-cancer-jab-trial-misses-primary-endpoint Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/gitex-global-2024-huawei-launches-a-series-of-industrial-digital-and-intelligent-transformation-solutions-and-flagship-products https://spypharm.com/gitex-global-2024-huawei-launches-a-series-of-industrial-digital-and-intelligent-transformation-solutions-and-flagship-products Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing https://spypharm.com/cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing Mon, 14 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/xtalpis-ai-biologics-discovery-platform-licensed-to-janssen-biotech https://spypharm.com/xtalpis-ai-biologics-discovery-platform-licensed-to-janssen-biotech Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/booster-therapeutics-to-develop-proteasome-activator-medicines https://spypharm.com/booster-therapeutics-to-develop-proteasome-activator-medicines Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/cphi-europe-targeting-supply-chain-bottlenecks-key-for-cell-and-gene-therapies https://spypharm.com/cphi-europe-targeting-supply-chain-bottlenecks-key-for-cell-and-gene-therapies Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/activist-investor-starboard-cries-foul-play-in-exec-u-turn-at-pfizer https://spypharm.com/activist-investor-starboard-cries-foul-play-in-exec-u-turn-at-pfizer Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/keybioscience-and-eli-lilly-extend-partnership-for-obesity-treatments https://spypharm.com/keybioscience-and-eli-lilly-extend-partnership-for-obesity-treatments Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/cphi-europe-overcoming-the-unique-challenges-with-high-concentration-mabs https://spypharm.com/cphi-europe-overcoming-the-unique-challenges-with-high-concentration-mabs Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/fda-adcom-votes-in-favour-of-stealths-barth-syndrome-drug https://spypharm.com/fda-adcom-votes-in-favour-of-stealths-barth-syndrome-drug Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/south-korean-company-dong-a-st-wins-fda-approval-for-stelara-biosimilar https://spypharm.com/south-korean-company-dong-a-st-wins-fda-approval-for-stelara-biosimilar Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/global-awareness-and-geographic-variations-of-plaque-psoriasis https://spypharm.com/global-awareness-and-geographic-variations-of-plaque-psoriasis Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/roche-wins-first-line-approval-for-pi3k-inhibitor-combo-in-breast-cancer https://spypharm.com/roche-wins-first-line-approval-for-pi3k-inhibitor-combo-in-breast-cancer Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/city-therapeutics-launches-with-135m-series-a-funding https://spypharm.com/city-therapeutics-launches-with-135m-series-a-funding Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/ipsens-elafibranor-gains-mhra-approval-for-pbc-treatment https://spypharm.com/ipsens-elafibranor-gains-mhra-approval-for-pbc-treatment Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/magazine-cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing https://spypharm.com/magazine-cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/could-preventative-care-save-the-future-of-the-nhs https://spypharm.com/could-preventative-care-save-the-future-of-the-nhs Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/emergent-to-donate-20000-narcan-doses-to-fight-opioid-overdoses-ceo-says https://spypharm.com/emergent-to-donate-20000-narcan-doses-to-fight-opioid-overdoses-ceo-says Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/fda-declines-to-approve-zealand-pharmas-hypoglycaemia-therapy-in-infants https://spypharm.com/fda-declines-to-approve-zealand-pharmas-hypoglycaemia-therapy-in-infants Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/purespring-secures-105m-to-start-phase-iii-trial-of-igan-gene-therapy https://spypharm.com/purespring-secures-105m-to-start-phase-iii-trial-of-igan-gene-therapy Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/clinical-dose-companies-in-contract-manufacturing-for-the-pharmaceutical-industry https://spypharm.com/clinical-dose-companies-in-contract-manufacturing-for-the-pharmaceutical-industry Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/anima-biotechs-machine-learning-programme-reveals-new-mrna-drug-targets https://spypharm.com/anima-biotechs-machine-learning-programme-reveals-new-mrna-drug-targets Thu, 10 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/msd-ventures-into-fibroblast-therapies-with-19bn-deal-with-mestag https://spypharm.com/msd-ventures-into-fibroblast-therapies-with-19bn-deal-with-mestag Thu, 10 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/mrna-licensing-agreements-double-with-million-dollar-deals https://spypharm.com/mrna-licensing-agreements-double-with-million-dollar-deals Tue, 08 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/neuvivo-makes-bid-to-enter-als-arena-with-immunotherapy-candidate https://spypharm.com/neuvivo-makes-bid-to-enter-als-arena-with-immunotherapy-candidate Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/productlife-boosts-drug-development-with-intiquan-acquisition https://spypharm.com/productlife-boosts-drug-development-with-intiquan-acquisition Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/health-canada-approves-telixs-illuccix-label-expansion https://spypharm.com/health-canada-approves-telixs-illuccix-label-expansion Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/onkure-and-reneo-pharmaceuticals-complete-merger https://spypharm.com/onkure-and-reneo-pharmaceuticals-complete-merger Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/nuhss-cd7-car-t-cell-therapy-shows-promise-for-leukaemia https://spypharm.com/nuhss-cd7-car-t-cell-therapy-shows-promise-for-leukaemia Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/ema-starts-review-into-hair-loss-drugs-about-potential-link-to-suicidal-thoughts https://spypharm.com/ema-starts-review-into-hair-loss-drugs-about-potential-link-to-suicidal-thoughts Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/oncolytics-targets-accelerated-approval-for-oncolytic-virus-therapy https://spypharm.com/oncolytics-targets-accelerated-approval-for-oncolytic-virus-therapy Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/activist-investor-starboard-forges-1bn-stake-in-pfizer-to-swing-profits https://spypharm.com/activist-investor-starboard-forges-1bn-stake-in-pfizer-to-swing-profits Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/teva-and-mabxience-partner-to-develop-biosimilar-candidate-for-oncology https://spypharm.com/teva-and-mabxience-partner-to-develop-biosimilar-candidate-for-oncology Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/bms-receives-fda-approval-for-opdivo-to-treat-nsclc https://spypharm.com/bms-receives-fda-approval-for-opdivo-to-treat-nsclc Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/resilience-secures-funds-to-enhance-production-of-essential-medicine-components https://spypharm.com/resilience-secures-funds-to-enhance-production-of-essential-medicine-components Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/a-rational-design-approach-to-rna-targeting-could-replace-large-scale-screening https://spypharm.com/a-rational-design-approach-to-rna-targeting-could-replace-large-scale-screening Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/editas-trades-part-of-vertex-crispr-therapy-licencing-rights-deal-for-57m https://spypharm.com/editas-trades-part-of-vertex-crispr-therapy-licencing-rights-deal-for-57m Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/wuxi-debates-sale-of-pharma-operations-as-biosecure-act-advances https://spypharm.com/wuxi-debates-sale-of-pharma-operations-as-biosecure-act-advances Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/the-benefits-of-using-a-nimble-platform-from-phase-to-phase https://spypharm.com/the-benefits-of-using-a-nimble-platform-from-phase-to-phase Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/nhs-proposes-phased-launch-for-eli-lillys-mounjaro https://spypharm.com/nhs-proposes-phased-launch-for-eli-lillys-mounjaro Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/fda-lifts-clinical-hold-on-aviditys-lead-antibody-conjugate-therapy-trial https://spypharm.com/fda-lifts-clinical-hold-on-aviditys-lead-antibody-conjugate-therapy-trial Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/recordati-to-acquire-worldwide-rights-to-sanofis-antibody-enjaymo https://spypharm.com/recordati-to-acquire-worldwide-rights-to-sanofis-antibody-enjaymo Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/social-media-algorithms-are-driving-the-glp-1-drugs-boom https://spypharm.com/social-media-algorithms-are-driving-the-glp-1-drugs-boom Fri, 04 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/gilead-signs-agreements-to-facilitate-access-to-hiv-prevention-drug https://spypharm.com/gilead-signs-agreements-to-facilitate-access-to-hiv-prevention-drug Fri, 04 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/eli-lilly-to-invest-45bn-for-drug-manufacturing-and-trial-medicine-production https://spypharm.com/eli-lilly-to-invest-45bn-for-drug-manufacturing-and-trial-medicine-production Fri, 04 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/immunoprecise-and-biotheus-partner-on-bispecific-antibodies-to-treat-cancer https://spypharm.com/immunoprecise-and-biotheus-partner-on-bispecific-antibodies-to-treat-cancer Fri, 04 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/novaliq-and-laboratoires-thea-announce-ec-approval-for-dry-eye-disease-therapy https://spypharm.com/novaliq-and-laboratoires-thea-announce-ec-approval-for-dry-eye-disease-therapy Fri, 04 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/resolution-scores-83m-to-develop-macrophage-cell-therapies https://spypharm.com/resolution-scores-83m-to-develop-macrophage-cell-therapies Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/enara-bio-secures-325m-for-dark-antigen-cancer-therapies https://spypharm.com/enara-bio-secures-325m-for-dark-antigen-cancer-therapies Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/healthcare-payers-for-the-pharmaceutical-industry https://spypharm.com/healthcare-payers-for-the-pharmaceutical-industry Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/a-rational-design-approach-to-rna-targeting-to-target-large-scale-screening https://spypharm.com/a-rational-design-approach-to-rna-targeting-to-target-large-scale-screening Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/chronic-diseases-as-urgent-as-climate-change-says-novo-nordisk-cso https://spypharm.com/chronic-diseases-as-urgent-as-climate-change-says-novo-nordisk-cso Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/bms-and-prime-ink-potential-35bn-deal-to-develop-t-cell-therapies https://spypharm.com/bms-and-prime-ink-potential-35bn-deal-to-develop-t-cell-therapies Wed, 02 Oct 2024 04:00:12 -0400 spectro https://spypharm.com/speciality-chemicals-for-the-pharmaceutical-industry https://spypharm.com/speciality-chemicals-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:11 -0400 spectro https://spypharm.com/ascendis-pharma-submits-sbla-for-growth-hormone-deficiency-therapy https://spypharm.com/ascendis-pharma-submits-sbla-for-growth-hormone-deficiency-therapy Wed, 02 Oct 2024 04:00:11 -0400 spectro https://spypharm.com/specialty-pharmacies-for-the-pharmaceutical-industry https://spypharm.com/specialty-pharmacies-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/fresenius-kabi-wins-fda-approval-for-stelara-biosimilar-otulfi https://spypharm.com/fresenius-kabi-wins-fda-approval-for-stelara-biosimilar-otulfi Wed, 02 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/robotics-companies-manufacturers-for-the-pharmaceutical-industry https://spypharm.com/robotics-companies-manufacturers-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/medication-adherence-solutions-for-the-pharmaceutical-industry https://spypharm.com/medication-adherence-solutions-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/genentech-buys-regors-cdk-inhibitors-in-850m-deal https://spypharm.com/genentech-buys-regors-cdk-inhibitors-in-850m-deal Wed, 02 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/the-course-to-forging-long-term-manufacturing-partnerships-for-gene-therapies https://spypharm.com/the-course-to-forging-long-term-manufacturing-partnerships-for-gene-therapies Wed, 02 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/sterilisation-solutions-equipment-and-services-for-the-pharmaceutical-industry https://spypharm.com/sterilisation-solutions-equipment-and-services-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/blockchain-leaders-finesse-tech-to-find-fake-drugs https://spypharm.com/blockchain-leaders-finesse-tech-to-find-fake-drugs Mon, 30 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-medidata-wins-awards-forclinical-data-studio-and-health-record-connect https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-medidata-wins-awards-forclinical-data-studio-and-health-record-connect Mon, 30 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/tempus-ai-expands-oncology-collaboration-with-takeda https://spypharm.com/tempus-ai-expands-oncology-collaboration-with-takeda Sat, 28 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/phare-bio-receives-arpa-h-funds-for-ai-drug-discovery-platform https://spypharm.com/phare-bio-receives-arpa-h-funds-for-ai-drug-discovery-platform Sat, 28 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/physicians-highlight-need-for-improved-non-opioid-treatments-for-opioid-use-disorder https://spypharm.com/physicians-highlight-need-for-improved-non-opioid-treatments-for-opioid-use-disorder Sat, 28 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/direct-to-patient-communication-bridging-the-gap-in-medication-adherence https://spypharm.com/direct-to-patient-communication-bridging-the-gap-in-medication-adherence Sat, 28 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/bms-wins-approval-for-schizophrenia-drug-acquired-from-karuna https://spypharm.com/bms-wins-approval-for-schizophrenia-drug-acquired-from-karuna Sat, 28 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/unicef-secures-one-million-mpox-vaccines-for-africa https://spypharm.com/unicef-secures-one-million-mpox-vaccines-for-africa Sat, 28 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/biomeas-stock-bounces-back-as-fda-lifts-clinical-hold-on-diabetes-trials https://spypharm.com/biomeas-stock-bounces-back-as-fda-lifts-clinical-hold-on-diabetes-trials Sat, 28 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/api-chemical-contract-manufacturing-companies-for-the-pharmaceutical-industry https://spypharm.com/api-chemical-contract-manufacturing-companies-for-the-pharmaceutical-industry Sat, 28 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/fda-greenlights-regenerons-dupixent-for-the-treatment-of-copd https://spypharm.com/fda-greenlights-regenerons-dupixent-for-the-treatment-of-copd Sat, 28 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/sanofiregenerons-dupixent-set-to-dominate-copd-biologics-market-following-fda-approval https://spypharm.com/sanofiregenerons-dupixent-set-to-dominate-copd-biologics-market-following-fda-approval Sat, 28 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/bavarian-nordic-gains-us-contract-for-additional-mpox-vaccine https://spypharm.com/bavarian-nordic-gains-us-contract-for-additional-mpox-vaccine Thu, 26 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/generatebiomedicines-and-novartis-link-on-protein-therapeutics-development https://spypharm.com/generatebiomedicines-and-novartis-link-on-protein-therapeutics-development Thu, 26 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/biotechnology-equipment-manufacturers-companies-and-suppliers-for-the-pharmaceutical-industry https://spypharm.com/biotechnology-equipment-manufacturers-companies-and-suppliers-for-the-pharmaceutical-industry Thu, 26 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/biologic-api-manufacturing-companies-protein-and-peptide-in-contract-manufacturing-for-the-pharmaceutical-industry https://spypharm.com/biologic-api-manufacturing-companies-protein-and-peptide-in-contract-manufacturing-for-the-pharmaceutical-industry Thu, 26 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/oral-solid-dose-manufacturing-companies-in-the-pharmaceutical-industry https://spypharm.com/oral-solid-dose-manufacturing-companies-in-the-pharmaceutical-industry Thu, 26 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/genespire-raises-52m-in-series-b-to-trial-paediatric-gene-therapy https://spypharm.com/genespire-raises-52m-in-series-b-to-trial-paediatric-gene-therapy Thu, 26 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/managing-temperature-sensitive-injectable-drugs-in-fill-finish-operations https://spypharm.com/managing-temperature-sensitive-injectable-drugs-in-fill-finish-operations Thu, 26 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/why-a-new-prescription-tracking-feature-on-the-nhs-app-is-important-for-pharmacists https://spypharm.com/why-a-new-prescription-tracking-feature-on-the-nhs-app-is-important-for-pharmacists Thu, 26 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/epigenetic-drugs-show-375-increase-in-series-a-venture-financing-in-2024 https://spypharm.com/epigenetic-drugs-show-375-increase-in-series-a-venture-financing-in-2024 Thu, 26 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/teva-touts-safety-profile-of-once-monthly-schizophrenia-therapy https://spypharm.com/teva-touts-safety-profile-of-once-monthly-schizophrenia-therapy Tue, 24 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/vicebio-secures-100m-to-advance-rsv-and-hmpv-vaccine-combo-to-phase-i https://spypharm.com/vicebio-secures-100m-to-advance-rsv-and-hmpv-vaccine-combo-to-phase-i Tue, 24 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/pharmaceutical-wholesalers-for-the-pharmaceutical-industry https://spypharm.com/pharmaceutical-wholesalers-for-the-pharmaceutical-industry Tue, 24 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/ipsens-iqirvo-wins-european-approval-for-primary-biliary-cholangitis https://spypharm.com/ipsens-iqirvo-wins-european-approval-for-primary-biliary-cholangitis Tue, 24 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/pharmaceutical-automation-and-equipment-for-the-pharmaceutical-industry https://spypharm.com/pharmaceutical-automation-and-equipment-for-the-pharmaceutical-industry Tue, 24 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/pharmaceutical-logistics-companies-and-supply-chain-specialists-for-the-pharmaceutical-industry https://spypharm.com/pharmaceutical-logistics-companies-and-supply-chain-specialists-for-the-pharmaceutical-industry Tue, 24 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/sanofi-gains-exclusivity-rights-to-ventyxs-cns-penetrant-drug-in-27m-deal https://spypharm.com/sanofi-gains-exclusivity-rights-to-ventyxs-cns-penetrant-drug-in-27m-deal Tue, 24 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/pancreatic-cancer-the-clinical-trial-landscape-and-progress-for-2024 https://spypharm.com/pancreatic-cancer-the-clinical-trial-landscape-and-progress-for-2024 Tue, 24 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/pharmaceutical-compliance-management-software-for-the-pharmaceutical-industry https://spypharm.com/pharmaceutical-compliance-management-software-for-the-pharmaceutical-industry Tue, 24 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/pharmaceutical-packaging-machines-and-labelling-companies https://spypharm.com/pharmaceutical-packaging-machines-and-labelling-companies Sun, 22 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/clinical-development-services-for-clinical-trials https://spypharm.com/clinical-development-services-for-clinical-trials Sun, 22 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/pharmaceutical-product-testing-inspection-and-detection-equipment-and-services https://spypharm.com/pharmaceutical-product-testing-inspection-and-detection-equipment-and-services Sun, 22 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/non-sterile-pharmaceutical-manufacturing-companies-commercial-dose-for-the-pharmaceutical-industry https://spypharm.com/non-sterile-pharmaceutical-manufacturing-companies-commercial-dose-for-the-pharmaceutical-industry Sun, 22 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/ema-approves-bavarian-nordics-mpox-vaccine-for-teenagers https://spypharm.com/ema-approves-bavarian-nordics-mpox-vaccine-for-teenagers Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/gc-therapeutics-secures-65m-to-launch-into-off-the-shelf-ipsc-therapy-space https://spypharm.com/gc-therapeutics-secures-65m-to-launch-into-off-the-shelf-ipsc-therapy-space Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/sanofi-eyes-approval-after-ms-therapy-slows-disease-progression-by-31 https://spypharm.com/sanofi-eyes-approval-after-ms-therapy-slows-disease-progression-by-31 Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/magazine-enhancing-therapy-adherence-with-prodrugs https://spypharm.com/magazine-enhancing-therapy-adherence-with-prodrugs Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/commercial-drug-manufacturing-companies-for-the-pharmaceutical-industry https://spypharm.com/commercial-drug-manufacturing-companies-for-the-pharmaceutical-industry Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/ai-boom-set-to-revolutionise-healthcare-in-europe https://spypharm.com/ai-boom-set-to-revolutionise-healthcare-in-europe Sun, 22 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/lupin-and-takeda-to-commercialise-vonoprazan-in-india https://spypharm.com/lupin-and-takeda-to-commercialise-vonoprazan-in-india Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/fda-approves-accord-biopharmas-hercessi-for-cancer-treatment https://spypharm.com/fda-approves-accord-biopharmas-hercessi-for-cancer-treatment Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/gavi-to-obtain-500000-mpox-vaccine-doses-from-bavarian-nordic https://spypharm.com/gavi-to-obtain-500000-mpox-vaccine-doses-from-bavarian-nordic Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/fda-approves-msds-keytruda-as-first-line-mpm-treatment https://spypharm.com/fda-approves-msds-keytruda-as-first-line-mpm-treatment Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/organon-makes-12bn-play-for-roivants-immuno-dermatology-subsidiary https://spypharm.com/organon-makes-12bn-play-for-roivants-immuno-dermatology-subsidiary Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/top-three-trends-in-precision-medicine https://spypharm.com/top-three-trends-in-precision-medicine Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/cancer-therapies-for-young-adults-the-need-for-tailored-treatment-and-diversity https://spypharm.com/cancer-therapies-for-young-adults-the-need-for-tailored-treatment-and-diversity Fri, 20 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/novo-nordisk-and-nanovation-sign-600m-deal-in-rare-and-cardiometabolic-diseases https://spypharm.com/novo-nordisk-and-nanovation-sign-600m-deal-in-rare-and-cardiometabolic-diseases Fri, 20 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/astrazenecas-fasenra-to-challenge-gsks-nucala-in-rare-vasculitis-after-fda-nod https://spypharm.com/astrazenecas-fasenra-to-challenge-gsks-nucala-in-rare-vasculitis-after-fda-nod Fri, 20 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/biotechs-investigate-ways-to-adapt-to-new-clinical-trial-regulation-and-economic-flux https://spypharm.com/biotechs-investigate-ways-to-adapt-to-new-clinical-trial-regulation-and-economic-flux Fri, 20 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/sanofi-begins-shipping-beyfortus-to-us-for-rsv-prevention-in-infants https://spypharm.com/sanofi-begins-shipping-beyfortus-to-us-for-rsv-prevention-in-infants Wed, 18 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/sbti-approves-piramal-pharmas-ghg-reduction-targets https://spypharm.com/sbti-approves-piramal-pharmas-ghg-reduction-targets Wed, 18 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/maxcyte-and-kamau-therapeutics-sign-platform-license-agreement https://spypharm.com/maxcyte-and-kamau-therapeutics-sign-platform-license-agreement Wed, 18 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/esmo-2024-bms-cuts-ties-as-immatics-regains-full-rights-to-bispecific https://spypharm.com/esmo-2024-bms-cuts-ties-as-immatics-regains-full-rights-to-bispecific Wed, 18 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/fda-grants-rmat-to-poseidas-car-t-cell-therapy-p-bcma-allo1 https://spypharm.com/fda-grants-rmat-to-poseidas-car-t-cell-therapy-p-bcma-allo1 Wed, 18 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/podcast-how-drones-are-transforming-the-clinical-supply-chain-in-africa https://spypharm.com/podcast-how-drones-are-transforming-the-clinical-supply-chain-in-africa Wed, 18 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/express-scripts-sues-ftc-and-demands-drug-pricing-report-retraction https://spypharm.com/express-scripts-sues-ftc-and-demands-drug-pricing-report-retraction Wed, 18 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/fda-lifts-partial-clinical-hold-on-zentalis-pharmas-cancer-wee1-inhibitor https://spypharm.com/fda-lifts-partial-clinical-hold-on-zentalis-pharmas-cancer-wee1-inhibitor Wed, 18 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/equillium-collaborates-with-vivtex-for-oral-formulation-of-autoimmune-therapy https://spypharm.com/equillium-collaborates-with-vivtex-for-oral-formulation-of-autoimmune-therapy Wed, 18 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/bicara-therapeutics-closes-362m-ipo-in-flurry-of-biotech-listing-activity https://spypharm.com/bicara-therapeutics-closes-362m-ipo-in-flurry-of-biotech-listing-activity Wed, 18 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/lillys-ebglyss-gains-fda-approval-for-patients-aged-12-and-older https://spypharm.com/lillys-ebglyss-gains-fda-approval-for-patients-aged-12-and-older Mon, 16 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/esmo-2024-tigit-race-tightens-with-first-look-at-gskiteoss-tigit-in-nsclc https://spypharm.com/esmo-2024-tigit-race-tightens-with-first-look-at-gskiteoss-tigit-in-nsclc Mon, 16 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases https://spypharm.com/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases Mon, 16 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/oncternal-stock-crashes-by-60-as-it-lays-off-staff-and-scraps-trials https://spypharm.com/oncternal-stock-crashes-by-60-as-it-lays-off-staff-and-scraps-trials Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/cidara-axes-30-of-staff-to-focus-on-flu-prevention-drug https://spypharm.com/cidara-axes-30-of-staff-to-focus-on-flu-prevention-drug Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/sobi-and-enable-injections-partner-for-aspaveli-distribution https://spypharm.com/sobi-and-enable-injections-partner-for-aspaveli-distribution Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/fda-approves-roches-tecentriq-hybreza-for-cancer https://spypharm.com/fda-approves-roches-tecentriq-hybreza-for-cancer Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/into-the-unknown-how-quickly-can-vaccines-be-developed-for-disease-x https://spypharm.com/into-the-unknown-how-quickly-can-vaccines-be-developed-for-disease-x Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/sanofi-signs-radioligand-therapy-licensing-deal-for-rare-cancers https://spypharm.com/sanofi-signs-radioligand-therapy-licensing-deal-for-rare-cancers Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/eli-lilly-to-invest-18bn-in-manufacturing-capacity-in-ireland https://spypharm.com/eli-lilly-to-invest-18bn-in-manufacturing-capacity-in-ireland Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/moderna-cuts-five-programmes-to-save-11bn-in-rd-costs https://spypharm.com/moderna-cuts-five-programmes-to-save-11bn-in-rd-costs Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/easd-2024-innovent-shows-off-mazdutides-efficacy-in-diabetes-and-obesity https://spypharm.com/easd-2024-innovent-shows-off-mazdutides-efficacy-in-diabetes-and-obesity Sat, 14 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/japan-approves-updated-covid-19-vaccine-to-tackle-jn1-variant https://spypharm.com/japan-approves-updated-covid-19-vaccine-to-tackle-jn1-variant Sat, 14 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/sanofi-inaugurates-vaccine-plant-in-neuville-sur-saone-france https://spypharm.com/sanofi-inaugurates-vaccine-plant-in-neuville-sur-saone-france Thu, 12 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/gilead-and-genesis-partner-to-create-novel-therapies-using-ai https://spypharm.com/gilead-and-genesis-partner-to-create-novel-therapies-using-ai Thu, 12 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/prodrugs-and-patents-enhancing-therapy-adherence-and-reducing-side-effects https://spypharm.com/prodrugs-and-patents-enhancing-therapy-adherence-and-reducing-side-effects Thu, 12 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/fda-grants-breakthrough-therapy-designation-to-neuraptives-ntx-001 https://spypharm.com/fda-grants-breakthrough-therapy-designation-to-neuraptives-ntx-001 Thu, 12 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/fda-approves-johnson-johnsons-tremfya-for-ulcerative-colitis https://spypharm.com/fda-approves-johnson-johnsons-tremfya-for-ulcerative-colitis Thu, 12 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/easd-2024-novo-nordisks-saxenda-shows-weight-loss-in-children https://spypharm.com/easd-2024-novo-nordisks-saxenda-shows-weight-loss-in-children Thu, 12 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/nanosyrinx-secures-funds-to-develop-biologic-therapeutics https://spypharm.com/nanosyrinx-secures-funds-to-develop-biologic-therapeutics Thu, 12 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/easd-2024-are-tetra-agonists-the-future-of-metabolic-diseases-treatment https://spypharm.com/easd-2024-are-tetra-agonists-the-future-of-metabolic-diseases-treatment Thu, 12 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/iba-venture-pantera-gains-134m-in-funding-to-scale-up-actinium-225-production https://spypharm.com/iba-venture-pantera-gains-134m-in-funding-to-scale-up-actinium-225-production Thu, 12 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/fda-grants-breakthrough-therapy-status-to-arrowheads-plozasiran https://spypharm.com/fda-grants-breakthrough-therapy-status-to-arrowheads-plozasiran Thu, 12 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-mantle-cell-lymphoma-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-mantle-cell-lymphoma-likelihood-of-approval Tue, 10 Sep 2024 04:00:13 -0400 spectro https://spypharm.com/sildenafil-citrate-by-xoma-royalty-for-female-hypoactive-sexual-desire-disorder-likelihood-of-approval https://spypharm.com/sildenafil-citrate-by-xoma-royalty-for-female-hypoactive-sexual-desire-disorder-likelihood-of-approval Tue, 10 Sep 2024 04:00:13 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-b-cell-non-hodgkin-lymphoma-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-b-cell-non-hodgkin-lymphoma-likelihood-of-approval Tue, 10 Sep 2024 04:00:12 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-follicular-lymphoma-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-follicular-lymphoma-likelihood-of-approval Tue, 10 Sep 2024 04:00:12 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval Tue, 10 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval Tue, 10 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval Tue, 10 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval Tue, 10 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval Tue, 10 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/cmn-005-by-coimmune-for-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval https://spypharm.com/cmn-005-by-coimmune-for-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval Tue, 10 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/gsks-asthma-blockbuster-nucala-secures-win-in-copd-phase-iii-trial https://spypharm.com/gsks-asthma-blockbuster-nucala-secures-win-in-copd-phase-iii-trial Sun, 08 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/fda-grants-odd-to-abderas-neuroendocrine-carcinoma-treatment https://spypharm.com/fda-grants-odd-to-abderas-neuroendocrine-carcinoma-treatment Sun, 08 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/evotec-partners-x-chem-for-tech-enabled-drug-discovery https://spypharm.com/evotec-partners-x-chem-for-tech-enabled-drug-discovery Sun, 08 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/fda-approves-amneal-and-shilpas-oncology-product-boruzu https://spypharm.com/fda-approves-amneal-and-shilpas-oncology-product-boruzu Sun, 08 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/investment-opportunities-in-atopic-dermatitis-may-drive-innovation https://spypharm.com/investment-opportunities-in-atopic-dermatitis-may-drive-innovation Sun, 08 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/men-taking-valproate-and-their-partners-warned-to-use-contraception-by-mhra https://spypharm.com/men-taking-valproate-and-their-partners-warned-to-use-contraception-by-mhra Sun, 08 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/nimmune-and-biotherapeutics-partner-on-precision-medicine-development https://spypharm.com/nimmune-and-biotherapeutics-partner-on-precision-medicine-development Sun, 08 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/biogens-higher-spinraza-dose-shows-better-efficacy-in-phase-iiiii-trial https://spypharm.com/biogens-higher-spinraza-dose-shows-better-efficacy-in-phase-iiiii-trial Sun, 08 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/after-failed-fsgs-bid-travere-wins-full-fda-approval-for-filspari-in-igan https://spypharm.com/after-failed-fsgs-bid-travere-wins-full-fda-approval-for-filspari-in-igan Sun, 08 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/in8bio-cuts-staff-and-pipeline-to-focus-on-aml-cell-therapy https://spypharm.com/in8bio-cuts-staff-and-pipeline-to-focus-on-aml-cell-therapy Fri, 06 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/nhs-england-offers-msd-belzutifan-for-von-hippel-lindau-disease https://spypharm.com/nhs-england-offers-msd-belzutifan-for-von-hippel-lindau-disease Fri, 06 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/uk-bans-xylazine-and-21-other-substances-to-fight-drug-abuse https://spypharm.com/uk-bans-xylazine-and-21-other-substances-to-fight-drug-abuse Fri, 06 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/arsenalbio-secures-325m-to-develop-cell-therapy-programmes https://spypharm.com/arsenalbio-secures-325m-to-develop-cell-therapy-programmes Fri, 06 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/lilly-and-eva-pharma-to-expand-baricitinib-access-in-africa https://spypharm.com/lilly-and-eva-pharma-to-expand-baricitinib-access-in-africa Fri, 06 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/esc-2024-insights-into-rna-as-therapeutic-target-and-tool https://spypharm.com/esc-2024-insights-into-rna-as-therapeutic-target-and-tool Fri, 06 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/moderna-mpox-mrna-vaccine-shows-early-promise-in-monkey-study https://spypharm.com/moderna-mpox-mrna-vaccine-shows-early-promise-in-monkey-study Fri, 06 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/esc-2024-new-pacman-ami-trial-analysis-sheds-insights-on-praluent-efficacy https://spypharm.com/esc-2024-new-pacman-ami-trial-analysis-sheds-insights-on-praluent-efficacy Fri, 06 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/lilly-partners-with-haya-for-lncrna-obesity-target-deal-worth-1bn https://spypharm.com/lilly-partners-with-haya-for-lncrna-obesity-target-deal-worth-1bn Fri, 06 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/egenesis-scoops-191m-for-genetically-modified-pig-kidney-transplant-trial https://spypharm.com/egenesis-scoops-191m-for-genetically-modified-pig-kidney-transplant-trial Fri, 06 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/uk-nhs-launches-vaccine-programme-for-rsv https://spypharm.com/uk-nhs-launches-vaccine-programme-for-rsv Wed, 04 Sep 2024 04:00:26 -0400 spectro https://spypharm.com/simcere-zaiming-and-targetrx-agree-tgrx-326-commercial-rights https://spypharm.com/simcere-zaiming-and-targetrx-agree-tgrx-326-commercial-rights Wed, 04 Sep 2024 04:00:26 -0400 spectro https://spypharm.com/syntekabio-and-enamine-partner-for-ai-based-drug-development https://spypharm.com/syntekabio-and-enamine-partner-for-ai-based-drug-development Wed, 04 Sep 2024 04:00:26 -0400 spectro https://spypharm.com/uae-mohap-and-novo-nordisk-partner-for-obesity-management https://spypharm.com/uae-mohap-and-novo-nordisk-partner-for-obesity-management Wed, 04 Sep 2024 04:00:26 -0400 spectro https://spypharm.com/skyline-wins-orphan-drug-designation-for-retinitis-pigmentosa-gene-therapy https://spypharm.com/skyline-wins-orphan-drug-designation-for-retinitis-pigmentosa-gene-therapy Wed, 04 Sep 2024 04:00:26 -0400 spectro https://spypharm.com/why-the-importer-of-record-ior-is-vital-in-the-clinical-supply-chain https://spypharm.com/why-the-importer-of-record-ior-is-vital-in-the-clinical-supply-chain Wed, 04 Sep 2024 04:00:26 -0400 spectro https://spypharm.com/esc-2024-beta-blocker-treatment-paradigm-shifts-for-myocardial-infarction https://spypharm.com/esc-2024-beta-blocker-treatment-paradigm-shifts-for-myocardial-infarction Wed, 04 Sep 2024 04:00:26 -0400 spectro https://spypharm.com/fda-grants-fast-track-status-to-innovents-ibi363-for-melanoma https://spypharm.com/fda-grants-fast-track-status-to-innovents-ibi363-for-melanoma Wed, 04 Sep 2024 04:00:25 -0400 spectro https://spypharm.com/regenxbio-touts-positive-data-for-rare-disease-drug-rgx-121 https://spypharm.com/regenxbio-touts-positive-data-for-rare-disease-drug-rgx-121 Wed, 04 Sep 2024 04:00:25 -0400 spectro https://spypharm.com/ocaliva-approval-in-europe-withdrawn-following-data-re-assessment https://spypharm.com/ocaliva-approval-in-europe-withdrawn-following-data-re-assessment Wed, 04 Sep 2024 04:00:25 -0400 spectro https://spypharm.com/esc-2024-cathedral-hf-trial-results-have-the-potential-to-reduce-polypharmacy https://spypharm.com/esc-2024-cathedral-hf-trial-results-have-the-potential-to-reduce-polypharmacy Mon, 02 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/diabetes-duration-has-minimal-impact-on-sglt2-inhibitor-efficacy-as-per-new-analysis https://spypharm.com/diabetes-duration-has-minimal-impact-on-sglt2-inhibitor-efficacy-as-per-new-analysis Mon, 02 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/esc-2024-study-highlights-potential-for-novartis-to-differentiate-in-hf-space https://spypharm.com/esc-2024-study-highlights-potential-for-novartis-to-differentiate-in-hf-space Mon, 02 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/generalized-pustular-psoriasis-gpp-drugs-in-development-2024 https://spypharm.com/generalized-pustular-psoriasis-gpp-drugs-in-development-2024 Sat, 31 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/frontotemporal-dementia-ftd-drugs-in-development-2024 https://spypharm.com/frontotemporal-dementia-ftd-drugs-in-development-2024 Sat, 31 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/aromatic-l-amino-acid-decarboxylase-aadc-deficiency-drugs-in-development-2024 https://spypharm.com/aromatic-l-amino-acid-decarboxylase-aadc-deficiency-drugs-in-development-2024 Sat, 31 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/non-infectious-uveitis-drugs-in-development-2024 https://spypharm.com/non-infectious-uveitis-drugs-in-development-2024 Sat, 31 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/esc-2024-latest-flow-trial-analysis-highlights-how-ozempic-can-benefit-ckd-patients https://spypharm.com/esc-2024-latest-flow-trial-analysis-highlights-how-ozempic-can-benefit-ckd-patients Sat, 31 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/jj-targets-generalised-myasthenia-gravis-landscape-with-nipocalimab https://spypharm.com/jj-targets-generalised-myasthenia-gravis-landscape-with-nipocalimab Sat, 31 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/esc-2024-amvuttra-data-signals-positive-prospects-in-cardiomyopathy-for-alnylam https://spypharm.com/esc-2024-amvuttra-data-signals-positive-prospects-in-cardiomyopathy-for-alnylam Sat, 31 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/esc-2024-obesity-drugs-emerge-as-attractive-tool-for-heart-failure-prevention https://spypharm.com/esc-2024-obesity-drugs-emerge-as-attractive-tool-for-heart-failure-prevention Sat, 31 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/acute-on-chronic-liver-failure-aclf-drugs-in-development-2024 https://spypharm.com/acute-on-chronic-liver-failure-aclf-drugs-in-development-2024 Sat, 31 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/atypical-teratoid-rhabdoid-tumor-drugs-in-development-2024 https://spypharm.com/atypical-teratoid-rhabdoid-tumor-drugs-in-development-2024 Sat, 31 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/singapore-approves-mpox-vaccine-as-it-adds-border-infection-checks https://spypharm.com/singapore-approves-mpox-vaccine-as-it-adds-border-infection-checks Thu, 29 Aug 2024 04:00:28 -0400 spectro https://spypharm.com/ec-upgrades-approval-for-jjs-rybrevantchemotherapy-combination-in-nsclc https://spypharm.com/ec-upgrades-approval-for-jjs-rybrevantchemotherapy-combination-in-nsclc Thu, 29 Aug 2024 04:00:28 -0400 spectro https://spypharm.com/bayer-teams-up-with-lncrna-focused-nextrna-in-547m-deal https://spypharm.com/bayer-teams-up-with-lncrna-focused-nextrna-in-547m-deal Thu, 29 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/arcus-biosciences-obtains-loan-facility-with-hercules-capital-worth-250m https://spypharm.com/arcus-biosciences-obtains-loan-facility-with-hercules-capital-worth-250m Thu, 29 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/soleno-wins-fda-priority-review-for-prader-willi-therapy https://spypharm.com/soleno-wins-fda-priority-review-for-prader-willi-therapy Thu, 29 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/navigator-gains-100m-in-series-a-funding-for-antibody-therapeutics https://spypharm.com/navigator-gains-100m-in-series-a-funding-for-antibody-therapeutics Thu, 29 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/ec-approves-astellas-padcev-for-urothelial-cancer https://spypharm.com/ec-approves-astellas-padcev-for-urothelial-cancer Thu, 29 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/oesophageal-cancer-the-global-clinical-trials-landscape-in-2024 https://spypharm.com/oesophageal-cancer-the-global-clinical-trials-landscape-in-2024 Thu, 29 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/pfizer-launches-digital-healthcare-platform-to-streamline-access https://spypharm.com/pfizer-launches-digital-healthcare-platform-to-streamline-access Thu, 29 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/eli-lillys-zepbound-to-be-issued-in-single-dose-vials-for-self-payers https://spypharm.com/eli-lillys-zepbound-to-be-issued-in-single-dose-vials-for-self-payers Thu, 29 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/ucb-to-divest-china-neurology-and-allergy-business-for-680m https://spypharm.com/ucb-to-divest-china-neurology-and-allergy-business-for-680m Tue, 27 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/china-nmpa-grants-approval-for-genfleets-fulzerasib-to-treat-lung-cancer https://spypharm.com/china-nmpa-grants-approval-for-genfleets-fulzerasib-to-treat-lung-cancer Tue, 27 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/msd-snags-european-approval-for-pulmonary-arterial-hypertension-therapy https://spypharm.com/msd-snags-european-approval-for-pulmonary-arterial-hypertension-therapy Tue, 27 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/celltrions-steqeyma-receives-ec-approval-for-chronic-inflammatory-diseases https://spypharm.com/celltrions-steqeyma-receives-ec-approval-for-chronic-inflammatory-diseases Tue, 27 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/invenras-antibody-gains-us-fda-designations-for-neuroblastoma-treatment https://spypharm.com/invenras-antibody-gains-us-fda-designations-for-neuroblastoma-treatment Tue, 27 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/janssens-balversa-receives-ec-approval-for-metastatic-urothelial-carcinoma https://spypharm.com/janssens-balversa-receives-ec-approval-for-metastatic-urothelial-carcinoma Tue, 27 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/astrazeneca-may-pull-plug-on-uk-vaccine-manufacturing-plans https://spypharm.com/astrazeneca-may-pull-plug-on-uk-vaccine-manufacturing-plans Sun, 25 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/rafael-holdings-and-cyclo-therapeutics-enter-merger-deal https://spypharm.com/rafael-holdings-and-cyclo-therapeutics-enter-merger-deal Sun, 25 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/vion-biosciences-acquires-echelon-biosciences https://spypharm.com/vion-biosciences-acquires-echelon-biosciences Sun, 25 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/fda-approves-updated-mrna-vaccines-for-covid-19 https://spypharm.com/fda-approves-updated-mrna-vaccines-for-covid-19 Sun, 25 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/eli-lilly-doubles-down-on-oblique-partnership-for-antibody-generation https://spypharm.com/eli-lilly-doubles-down-on-oblique-partnership-for-antibody-generation Sun, 25 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/jazzs-cannabidiol-therapy-flunks-in-japanese-phase-iii-trial https://spypharm.com/jazzs-cannabidiol-therapy-flunks-in-japanese-phase-iii-trial Sun, 25 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/a-comprehensive-guide-to-supply-chain-management-for-specialty-drugs https://spypharm.com/a-comprehensive-guide-to-supply-chain-management-for-specialty-drugs Sun, 25 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/aquestive-therapeutics-gets-grant-for-enhanced-pharmaceutical-compositions-for-active-component-permeation https://spypharm.com/aquestive-therapeutics-gets-grant-for-enhanced-pharmaceutical-compositions-for-active-component-permeation Fri, 23 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/acorda-therapeutics-gets-grant-for-sustained-release-4-aminopyridine-tablets-for-neurological-disorders https://spypharm.com/acorda-therapeutics-gets-grant-for-sustained-release-4-aminopyridine-tablets-for-neurological-disorders Fri, 23 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/lyra-therapeutics-gets-grant-for-coated-scaffold-for-treating-chronic-sinusitis https://spypharm.com/lyra-therapeutics-gets-grant-for-coated-scaffold-for-treating-chronic-sinusitis Fri, 23 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/verve-therapeutics-gets-grant-for-gene-editing-compositions-to-lower-ldl-cholesterol-levels https://spypharm.com/verve-therapeutics-gets-grant-for-gene-editing-compositions-to-lower-ldl-cholesterol-levels Fri, 23 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/frequency-therapeutics-gets-grant-for-oligonucleotide-compositions-for-treating-mrna-related-disorders https://spypharm.com/frequency-therapeutics-gets-grant-for-oligonucleotide-compositions-for-treating-mrna-related-disorders Fri, 23 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/codiak-biosciences-gets-grant-for-extracellular-vesicles-for-disease-treatment-and-prevention https://spypharm.com/codiak-biosciences-gets-grant-for-extracellular-vesicles-for-disease-treatment-and-prevention Fri, 23 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/optibiotix-health-gets-grant-for-modified-prebiotic-oligosaccharides-with-increased-sweetness-value https://spypharm.com/optibiotix-health-gets-grant-for-modified-prebiotic-oligosaccharides-with-increased-sweetness-value Fri, 23 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/orion-gets-grant-for-cyp11a1-inhibitors-for-treating-prostate-cancer https://spypharm.com/orion-gets-grant-for-cyp11a1-inhibitors-for-treating-prostate-cancer Fri, 23 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/ocular-therapeutix-gets-grant-for-intracanalicular-injectable-applicator-device-for-drug-delivery https://spypharm.com/ocular-therapeutix-gets-grant-for-intracanalicular-injectable-applicator-device-for-drug-delivery Fri, 23 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/novartis-and-versant-launch-borealis-biosciences-with-150m https://spypharm.com/novartis-and-versant-launch-borealis-biosciences-with-150m Fri, 23 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/emergent-joins-mpox-fight-with-50000-vaccine-dose-donation-to-africa https://spypharm.com/emergent-joins-mpox-fight-with-50000-vaccine-dose-donation-to-africa Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/glp-1r-market-a-two-horse-race https://spypharm.com/glp-1r-market-a-two-horse-race Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/accenture-invests-in-earli-to-advance-early-cancer-detection-tech https://spypharm.com/accenture-invests-in-earli-to-advance-early-cancer-detection-tech Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/liquidias-yutrepia-inhalation-powder-gains-tentative-fda-approval https://spypharm.com/liquidias-yutrepia-inhalation-powder-gains-tentative-fda-approval Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/nmpa-approves-astellas-padcev-for-advanced-urothelial-cancer https://spypharm.com/nmpa-approves-astellas-padcev-for-advanced-urothelial-cancer Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/jjs-rybrevant-plus-lazcluze-combination-gets-fda-approval-in-nsclc https://spypharm.com/jjs-rybrevant-plus-lazcluze-combination-gets-fda-approval-in-nsclc Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/realta-secures-fda-orphan-drug-and-fast-track-designations-for-gvhd-therapy https://spypharm.com/realta-secures-fda-orphan-drug-and-fast-track-designations-for-gvhd-therapy Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/top-20-biopharmas-market-cap-up-43-in-q2-2024-as-glp-1-drug-innovators-hold-top-spots https://spypharm.com/top-20-biopharmas-market-cap-up-43-in-q2-2024-as-glp-1-drug-innovators-hold-top-spots Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/colombias-president-signs-law-to-strengthen-pharmaceutical-sector https://spypharm.com/colombias-president-signs-law-to-strengthen-pharmaceutical-sector Wed, 21 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/adcendo-and-multitude-ink-adc-deal-potentially-worth-1bn https://spypharm.com/adcendo-and-multitude-ink-adc-deal-potentially-worth-1bn Wed, 21 Aug 2024 04:00:23 -0400 spectro https://spypharm.com/lykos-cuts-team-by-75-vows-to-keep-mdma-program-despite-fda-veto https://spypharm.com/lykos-cuts-team-by-75-vows-to-keep-mdma-program-despite-fda-veto Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/hoth-and-aronnax-partner-for-ht-kit-cancer-therapy-development https://spypharm.com/hoth-and-aronnax-partner-for-ht-kit-cancer-therapy-development Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/astrazeneca-wins-approval-for-imfinzi-in-nsclc-perioperative-setting https://spypharm.com/astrazeneca-wins-approval-for-imfinzi-in-nsclc-perioperative-setting Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/bavarian-nordic-seeks-authorisation-for-mpox-vaccines-use-in-adolescents https://spypharm.com/bavarian-nordic-seeks-authorisation-for-mpox-vaccines-use-in-adolescents Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/armed-with-phase-iii-win-incyte-eyes-label-expansion-for-monjuvi https://spypharm.com/armed-with-phase-iii-win-incyte-eyes-label-expansion-for-monjuvi Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/fda-accepts-decipheras-vimseltinib-nda-for-priority-review https://spypharm.com/fda-accepts-decipheras-vimseltinib-nda-for-priority-review Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/the-genomic-medicine-revolution-multi-modality-approaches-in-advanced-therapies https://spypharm.com/the-genomic-medicine-revolution-multi-modality-approaches-in-advanced-therapies Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/nuntius-partners-with-taiho-to-develop-mrna-cancer-therapies https://spypharm.com/nuntius-partners-with-taiho-to-develop-mrna-cancer-therapies Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/astrazenecas-sbla-for-ls-sclc-treatment-gains-fda-priority-review https://spypharm.com/astrazenecas-sbla-for-ls-sclc-treatment-gains-fda-priority-review Sat, 17 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/pfizer-and-biontechs-covid-19flu-combination-vaccine-falters-in-phase-iii-readout https://spypharm.com/pfizer-and-biontechs-covid-19flu-combination-vaccine-falters-in-phase-iii-readout Sat, 17 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/northstar-and-convergent-expand-deal-for-prostate-cancer-drug https://spypharm.com/northstar-and-convergent-expand-deal-for-prostate-cancer-drug Thu, 15 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/uae-approves-bioarctic-and-eisais-leqembi-for-alzheimers-disease https://spypharm.com/uae-approves-bioarctic-and-eisais-leqembi-for-alzheimers-disease Thu, 15 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/china-approves-astrazeneca-daiichi-sankyos-gastric-cancer-therapy https://spypharm.com/china-approves-astrazeneca-daiichi-sankyos-gastric-cancer-therapy Thu, 15 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/eli-lilly-inaugurates-rd-facility-in-boston-us https://spypharm.com/eli-lilly-inaugurates-rd-facility-in-boston-us Thu, 15 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/acelyrin-deprioritises-lead-therapy-despite-phase-iii-win-fires-33-of-staff https://spypharm.com/acelyrin-deprioritises-lead-therapy-despite-phase-iii-win-fires-33-of-staff Thu, 15 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/diabesity-overlapping-pathophysiology-informs-multi-indication-treatment https://spypharm.com/diabesity-overlapping-pathophysiology-informs-multi-indication-treatment Thu, 15 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/us-judge-denies-initial-attempt-by-novartis-to-block-generic-entresto-launch https://spypharm.com/us-judge-denies-initial-attempt-by-novartis-to-block-generic-entresto-launch Thu, 15 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/replimune-kickstarts-phase-iii-melanoma-trial-studying-rp1-immunotherapy https://spypharm.com/replimune-kickstarts-phase-iii-melanoma-trial-studying-rp1-immunotherapy Thu, 15 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/kezar-stalls-solid-tumour-trial-to-focus-on-autoimmune-disease-candidate https://spypharm.com/kezar-stalls-solid-tumour-trial-to-focus-on-autoimmune-disease-candidate Thu, 15 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/bavarian-nordic-outlays-215000-mpox-vaccine-dose-supply-to-african-countries https://spypharm.com/bavarian-nordic-outlays-215000-mpox-vaccine-dose-supply-to-african-countries Thu, 15 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/sable-therapeutics-and-columbia-sign-deal-on-obesity-treatments https://spypharm.com/sable-therapeutics-and-columbia-sign-deal-on-obesity-treatments Tue, 13 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/ars-pharmaceuticals-anaphylaxis-nasal-spray-gains-fda-approval https://spypharm.com/ars-pharmaceuticals-anaphylaxis-nasal-spray-gains-fda-approval Tue, 13 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/blue-earth-and-seibersdorf-expand-radiopharmaceutical-manufacture-deal https://spypharm.com/blue-earth-and-seibersdorf-expand-radiopharmaceutical-manufacture-deal Tue, 13 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/era-of-adcs-pharma-companies-innovate-to-stand-out-in-a-buzzing-market https://spypharm.com/era-of-adcs-pharma-companies-innovate-to-stand-out-in-a-buzzing-market Tue, 13 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/pfizer-touts-positive-topline-data-for-rsv-vaccine-abrysvo https://spypharm.com/pfizer-touts-positive-topline-data-for-rsv-vaccine-abrysvo Tue, 13 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/fda-approves-iaso-bios-ind-for-equecabtagene-autoleucel https://spypharm.com/fda-approves-iaso-bios-ind-for-equecabtagene-autoleucel Tue, 13 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/fda-approves-sandozs-enzeevu-as-eylea-biosimilar-saga-continues https://spypharm.com/fda-approves-sandozs-enzeevu-as-eylea-biosimilar-saga-continues Tue, 13 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/patient-with-rare-neurodegenerative-disorder-improves-with-non-profits-aso-therapy https://spypharm.com/patient-with-rare-neurodegenerative-disorder-improves-with-non-profits-aso-therapy Tue, 13 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/leap-consulting-launches-practice-to-assist-labs-with-fdas-ldt-ruling https://spypharm.com/leap-consulting-launches-practice-to-assist-labs-with-fdas-ldt-ruling Tue, 13 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/fda-rejects-lykos-mdma-therapy-asks-for-another-phase-iii-trial https://spypharm.com/fda-rejects-lykos-mdma-therapy-asks-for-another-phase-iii-trial Tue, 13 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/momentum-biotechnologies-and-cube-biotech-link-for-therapeutic-solutions https://spypharm.com/momentum-biotechnologies-and-cube-biotech-link-for-therapeutic-solutions Sun, 11 Aug 2024 04:00:07 -0400 spectro https://spypharm.com/recursion-and-exscientia-merge-to-form-drug-discovery-company https://spypharm.com/recursion-and-exscientia-merge-to-form-drug-discovery-company Sun, 11 Aug 2024 04:00:07 -0400 spectro https://spypharm.com/msd-sets-sights-on-bispecific-antibody-market-with-curon-acqusition https://spypharm.com/msd-sets-sights-on-bispecific-antibody-market-with-curon-acqusition Sun, 11 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/adaptimmune-leads-in-soft-tissue-sarcoma-therapy-with-first-tcr-approval https://spypharm.com/adaptimmune-leads-in-soft-tissue-sarcoma-therapy-with-first-tcr-approval Sun, 11 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/gilead-sciences-reports-net-income-rise-in-q2-2024 https://spypharm.com/gilead-sciences-reports-net-income-rise-in-q2-2024 Sun, 11 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/wuxi-biologics-and-medigene-link-on-t-cell-engagers-for-cancer https://spypharm.com/wuxi-biologics-and-medigene-link-on-t-cell-engagers-for-cancer Sun, 11 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/nice-supports-theramexs-eladynos-for-post-menopause-osteoporosis https://spypharm.com/nice-supports-theramexs-eladynos-for-post-menopause-osteoporosis Sun, 11 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/eli-lilly-boosts-sales-forecast-by-3bn-as-diabetes-and-weight-loss-drugs-propel-revenue https://spypharm.com/eli-lilly-boosts-sales-forecast-by-3bn-as-diabetes-and-weight-loss-drugs-propel-revenue Sun, 11 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/an2-slashes-staff-by-50-after-lead-antibiotic-flunks-in-phase-iiiii-trial https://spypharm.com/an2-slashes-staff-by-50-after-lead-antibiotic-flunks-in-phase-iiiii-trial Sun, 11 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/how-the-glp-1-receptor-agonist-market-could-hit-168bn-by-2033 https://spypharm.com/how-the-glp-1-receptor-agonist-market-could-hit-168bn-by-2033 Sun, 11 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/takedas-adzynma-gains-eu-approval-for-cttp-treatment https://spypharm.com/takedas-adzynma-gains-eu-approval-for-cttp-treatment Fri, 09 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/amneals-crexont-gains-fda-approval-for-parkinsons-treatment https://spypharm.com/amneals-crexont-gains-fda-approval-for-parkinsons-treatment Fri, 09 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/gsks-jemperli-approved-for-advanced-endometrial-cancer-in-singapore https://spypharm.com/gsks-jemperli-approved-for-advanced-endometrial-cancer-in-singapore Fri, 09 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/us-fda-approves-novartis-fabhalta-in-igan-treatment https://spypharm.com/us-fda-approves-novartis-fabhalta-in-igan-treatment Fri, 09 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/addressing-industry-challenges-through-flexible-personalized-ecoa-solutions https://spypharm.com/addressing-industry-challenges-through-flexible-personalized-ecoa-solutions Fri, 09 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/conduit-acquires-three-first-in-class-assets-from-astrazeneca https://spypharm.com/conduit-acquires-three-first-in-class-assets-from-astrazeneca Fri, 09 Aug 2024 04:00:23 -0400 spectro https://spypharm.com/bavarian-nordic-tops-up-us-smallpoxmpox-vaccine-stockpile-with-1568m-order https://spypharm.com/bavarian-nordic-tops-up-us-smallpoxmpox-vaccine-stockpile-with-1568m-order Fri, 09 Aug 2024 04:00:23 -0400 spectro https://spypharm.com/crispr-based-casgevy-is-made-accessible-in-england-following-nice-guidance https://spypharm.com/crispr-based-casgevy-is-made-accessible-in-england-following-nice-guidance Fri, 09 Aug 2024 04:00:23 -0400 spectro https://spypharm.com/pharmacosmos-ventures-into-oncology-and-merges-with-g1-therapeutics https://spypharm.com/pharmacosmos-ventures-into-oncology-and-merges-with-g1-therapeutics Fri, 09 Aug 2024 04:00:23 -0400 spectro https://spypharm.com/purdue-receives-clearance-for-opioid-overdose-injector-for-younger-individuals https://spypharm.com/purdue-receives-clearance-for-opioid-overdose-injector-for-younger-individuals Fri, 09 Aug 2024 04:00:23 -0400 spectro https://spypharm.com/how-saas-platforms-are-breaking-the-mold-for-clinical-trials https://spypharm.com/how-saas-platforms-are-breaking-the-mold-for-clinical-trials Wed, 07 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/sk-pharmteco-and-rznomics-sign-mou-to-develop-gene-therapies https://spypharm.com/sk-pharmteco-and-rznomics-sign-mou-to-develop-gene-therapies Wed, 07 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/fda-grants-rpdd-to-meta-pharmaceuticals-hyperoxaluria-drug https://spypharm.com/fda-grants-rpdd-to-meta-pharmaceuticals-hyperoxaluria-drug Wed, 07 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/global-stock-market-crash-likely-to-delay-biotech-ipos https://spypharm.com/global-stock-market-crash-likely-to-delay-biotech-ipos Wed, 07 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/malaysia-approves-antengenes-xpovio-nda-for-multiple-myeloma https://spypharm.com/malaysia-approves-antengenes-xpovio-nda-for-multiple-myeloma Wed, 07 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/pharma-casts-a-wide-net-to-hook-opportunities-in-metabolic-disorders https://spypharm.com/pharma-casts-a-wide-net-to-hook-opportunities-in-metabolic-disorders Wed, 07 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/developing-high-potent-apis-the-necessary-steps-to-follow https://spypharm.com/developing-high-potent-apis-the-necessary-steps-to-follow Wed, 07 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/chime-looks-to-expand-manufacturing-capacity-and-establish-european-presence https://spypharm.com/chime-looks-to-expand-manufacturing-capacity-and-establish-european-presence Wed, 07 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/concentric-analgesics-highlights-data-on-vocacapsaicin-for-pain-relief https://spypharm.com/concentric-analgesics-highlights-data-on-vocacapsaicin-for-pain-relief Wed, 07 Aug 2024 04:00:25 -0400 spectro https://spypharm.com/q2-2024-update-electronic-medical-record-emr-systems-related-private-equity-activity-in-the-pharmaceutical-industry https://spypharm.com/q2-2024-update-electronic-medical-record-emr-systems-related-private-equity-activity-in-the-pharmaceutical-industry Wed, 07 Aug 2024 04:00:24 -0400 spectro https://spypharm.com/cellectis-starts-alemtuzumab-revival-with-fda-orphan-drug-win-in-leukaemia https://spypharm.com/cellectis-starts-alemtuzumab-revival-with-fda-orphan-drug-win-in-leukaemia Sat, 03 Aug 2024 04:00:22 -0400 spectro https://spypharm.com/rejuvenate-and-sas-partner-to-harness-ai-for-age-related-diseases https://spypharm.com/rejuvenate-and-sas-partner-to-harness-ai-for-age-related-diseases Sat, 03 Aug 2024 04:00:22 -0400 spectro https://spypharm.com/sanofi-invests-14bn-in-insulin-production-in-germany https://spypharm.com/sanofi-invests-14bn-in-insulin-production-in-germany Sat, 03 Aug 2024 04:00:22 -0400 spectro https://spypharm.com/fda-expands-gsks-jemperli-approval-for-endometrial-cancer https://spypharm.com/fda-expands-gsks-jemperli-approval-for-endometrial-cancer Sat, 03 Aug 2024 04:00:22 -0400 spectro https://spypharm.com/merck-buys-mirus-bio-to-boost-viral-vector-bioprocessing-capacity https://spypharm.com/merck-buys-mirus-bio-to-boost-viral-vector-bioprocessing-capacity Sat, 03 Aug 2024 04:00:22 -0400 spectro https://spypharm.com/abbvie-acquires-cerevel-therapeutics-for-87bn https://spypharm.com/abbvie-acquires-cerevel-therapeutics-for-87bn Sat, 03 Aug 2024 04:00:22 -0400 spectro https://spypharm.com/aaic-2024-eisai-presents-positive-long-term-data-with-leqembi https://spypharm.com/aaic-2024-eisai-presents-positive-long-term-data-with-leqembi Sat, 03 Aug 2024 04:00:22 -0400 spectro https://spypharm.com/adaptimmunes-tecelra-gains-accelerated-approval-for-synovial-sarcoma https://spypharm.com/adaptimmunes-tecelra-gains-accelerated-approval-for-synovial-sarcoma Sat, 03 Aug 2024 04:00:21 -0400 spectro https://spypharm.com/vir-bio-trims-staff-and-pipeline-to-focus-on-sanofi-licensed-programmes https://spypharm.com/vir-bio-trims-staff-and-pipeline-to-focus-on-sanofi-licensed-programmes Sat, 03 Aug 2024 04:00:21 -0400 spectro https://spypharm.com/casgevy-launch-sequence-and-price-analysis-of-the-first-marketed-crispr-therapy https://spypharm.com/casgevy-launch-sequence-and-price-analysis-of-the-first-marketed-crispr-therapy Sat, 03 Aug 2024 04:00:21 -0400 spectro https://spypharm.com/novo-faces-growth-challenges-despite-glp-1-receptor-agonist-obesity-boom https://spypharm.com/novo-faces-growth-challenges-despite-glp-1-receptor-agonist-obesity-boom Thu, 01 Aug 2024 04:00:27 -0400 spectro https://spypharm.com/bayer-in-ecommerce-theme-innovation-strategy https://spypharm.com/bayer-in-ecommerce-theme-innovation-strategy Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/bayer-in-batteries-theme-innovation-strategy https://spypharm.com/bayer-in-batteries-theme-innovation-strategy Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/amgen-in-mobile-theme-innovation-strategy https://spypharm.com/amgen-in-mobile-theme-innovation-strategy Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/amgen-in-internet-of-things-theme-innovation-strategy https://spypharm.com/amgen-in-internet-of-things-theme-innovation-strategy Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/magazine-left-in-limbo-whenpharma-halts-rare-disease-research https://spypharm.com/magazine-left-in-limbo-whenpharma-halts-rare-disease-research Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/fibrogen-axes-75-of-staff-after-lead-cancer-therapy-fails-in-phase-iii-trials https://spypharm.com/fibrogen-axes-75-of-staff-after-lead-cancer-therapy-fails-in-phase-iii-trials Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/imunons-shares-soar-after-il-12-therapy-success-in-phase-ii-trial https://spypharm.com/imunons-shares-soar-after-il-12-therapy-success-in-phase-ii-trial Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/vertexs-blockbuster-in-waiting-painkiller-suzetrigine-set-for-fda-review-next-year https://spypharm.com/vertexs-blockbuster-in-waiting-painkiller-suzetrigine-set-for-fda-review-next-year Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/revenue-growth-for-13-of-top-20-biopharmas-with-obesity-drug-successes-in-2023 https://spypharm.com/revenue-growth-for-13-of-top-20-biopharmas-with-obesity-drug-successes-in-2023 Thu, 01 Aug 2024 04:00:26 -0400 spectro https://spypharm.com/eu-chmp-snubs-biogen-and-eisais-alzheimers-therapy-leqembi https://spypharm.com/eu-chmp-snubs-biogen-and-eisais-alzheimers-therapy-leqembi Tue, 30 Jul 2024 04:00:25 -0400 spectro https://spypharm.com/attralus-set-for-amyloidosis-assets-european-orphan-designations https://spypharm.com/attralus-set-for-amyloidosis-assets-european-orphan-designations Tue, 30 Jul 2024 04:00:25 -0400 spectro https://spypharm.com/ec-approves-measure-to-produce-radioisotopes-for-cancer https://spypharm.com/ec-approves-measure-to-produce-radioisotopes-for-cancer Tue, 30 Jul 2024 04:00:25 -0400 spectro https://spypharm.com/fda-approves-luye-pharmas-erzofri-for-schizophrenia https://spypharm.com/fda-approves-luye-pharmas-erzofri-for-schizophrenia Tue, 30 Jul 2024 04:00:25 -0400 spectro https://spypharm.com/chmp-backs-msds-keytruda-approval-for-urothelial-carcinoma https://spypharm.com/chmp-backs-msds-keytruda-approval-for-urothelial-carcinoma Tue, 30 Jul 2024 04:00:25 -0400 spectro https://spypharm.com/new-ai-model-boosts-early-osteoporosis-diagnosis-for-ageing-populations https://spypharm.com/new-ai-model-boosts-early-osteoporosis-diagnosis-for-ageing-populations Tue, 30 Jul 2024 04:00:25 -0400 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-securechek-ai https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-securechek-ai Tue, 30 Jul 2024 04:00:25 -0400 spectro https://spypharm.com/bristol-myers-squibb-reports-dip-in-net-income-for-q2-2024 https://spypharm.com/bristol-myers-squibb-reports-dip-in-net-income-for-q2-2024 Tue, 30 Jul 2024 04:00:25 -0400 spectro https://spypharm.com/aaic-2024-the-evolution-of-alzheimers-clinical-trials https://spypharm.com/aaic-2024-the-evolution-of-alzheimers-clinical-trials Tue, 30 Jul 2024 04:00:24 -0400 spectro https://spypharm.com/chmp-backs-boehringers-spevigo-for-preventing-rare-psoriasis-flare-ups https://spypharm.com/chmp-backs-boehringers-spevigo-for-preventing-rare-psoriasis-flare-ups Tue, 30 Jul 2024 04:00:24 -0400 spectro https://spypharm.com/cue-biopharma-downsizes-to-focus-on-autoimmune-pipeline https://spypharm.com/cue-biopharma-downsizes-to-focus-on-autoimmune-pipeline Sun, 28 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/roche-records-4-decline-in-h1-2024-net-income https://spypharm.com/roche-records-4-decline-in-h1-2024-net-income Sun, 28 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/mankind-pharma-acquires-bharat-serums-and-vaccines-for-16bn https://spypharm.com/mankind-pharma-acquires-bharat-serums-and-vaccines-for-16bn Sun, 28 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/abbvies-q2-2024-net-earnings-drop-to-137bn https://spypharm.com/abbvies-q2-2024-net-earnings-drop-to-137bn Sun, 28 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/ec-conditionally-approves-pfizers-haemophilia-b-gene-therapy https://spypharm.com/ec-conditionally-approves-pfizers-haemophilia-b-gene-therapy Sun, 28 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/inside-the-efforts-to-rescue-a-rare-disease-gene-therapy https://spypharm.com/inside-the-efforts-to-rescue-a-rare-disease-gene-therapy Sun, 28 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/ema-backs-wegovy-cardiovascular-label-update-as-novo-seeks-eu-coverage https://spypharm.com/ema-backs-wegovy-cardiovascular-label-update-as-novo-seeks-eu-coverage Sun, 28 Jul 2024 04:00:06 -0400 spectro https://spypharm.com/fda-committee-proposes-overhaul-of-perioperative-lung-cancer-trials https://spypharm.com/fda-committee-proposes-overhaul-of-perioperative-lung-cancer-trials Sun, 28 Jul 2024 04:00:06 -0400 spectro https://spypharm.com/fda-approves-sun-pharmas-jak-inhibitor-for-alopecia https://spypharm.com/fda-approves-sun-pharmas-jak-inhibitor-for-alopecia Sun, 28 Jul 2024 04:00:06 -0400 spectro https://spypharm.com/bavarian-nordic-wins-positive-chmp-opinion-to-amend-imvanex-approval https://spypharm.com/bavarian-nordic-wins-positive-chmp-opinion-to-amend-imvanex-approval Sun, 28 Jul 2024 04:00:06 -0400 spectro https://spypharm.com/mhra-approves-pfizer-biontechs-comirnaty-jn1-vaccine https://spypharm.com/mhra-approves-pfizer-biontechs-comirnaty-jn1-vaccine Fri, 26 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/bioatla-receives-fda-fast-track-designation-for-ozuriftamab-vedotin https://spypharm.com/bioatla-receives-fda-fast-track-designation-for-ozuriftamab-vedotin Fri, 26 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/the-potential-of-3d-printing-in-drug-development-and-delivery https://spypharm.com/the-potential-of-3d-printing-in-drug-development-and-delivery Fri, 26 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/sandoz-launches-ustekinumab-biosimilar-in-europe https://spypharm.com/sandoz-launches-ustekinumab-biosimilar-in-europe Fri, 26 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/consynance-wins-fda-designation-for-prader-willi-syndrome-therapy https://spypharm.com/consynance-wins-fda-designation-for-prader-willi-syndrome-therapy Fri, 26 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/fda-agrees-wider-use-of-biomarins-brineura-for-cln2 https://spypharm.com/fda-agrees-wider-use-of-biomarins-brineura-for-cln2 Fri, 26 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/nice-recommends-boehringers-tenecteplase-for-nhs-stroke-care https://spypharm.com/nice-recommends-boehringers-tenecteplase-for-nhs-stroke-care Fri, 26 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/dren-bio-and-novartis-link-on-bispecific-antibodies-for-cancer https://spypharm.com/dren-bio-and-novartis-link-on-bispecific-antibodies-for-cancer Fri, 26 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/ac-immune-wins-fda-fast-track-for-alzheimers-vaccine-candidate https://spypharm.com/ac-immune-wins-fda-fast-track-for-alzheimers-vaccine-candidate Fri, 26 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/ipsen-outlines-461m-for-ex-us-rights-to-day-ones-glioma-therapy https://spypharm.com/ipsen-outlines-461m-for-ex-us-rights-to-day-ones-glioma-therapy Fri, 26 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/agilent-agrees-to-acquire-biovectra-for-925m https://spypharm.com/agilent-agrees-to-acquire-biovectra-for-925m Wed, 24 Jul 2024 04:00:17 -0400 spectro https://spypharm.com/fda-approves-samsung-bioepis-epysqli-as-soliris-biosimilar https://spypharm.com/fda-approves-samsung-bioepis-epysqli-as-soliris-biosimilar Wed, 24 Jul 2024 04:00:17 -0400 spectro https://spypharm.com/johnson-johnson-submits-snda-for-spravato-to-treat-depression https://spypharm.com/johnson-johnson-submits-snda-for-spravato-to-treat-depression Wed, 24 Jul 2024 04:00:17 -0400 spectro https://spypharm.com/grunenthal-gains-valinor-pharma-and-constipation-drug-movantik https://spypharm.com/grunenthal-gains-valinor-pharma-and-constipation-drug-movantik Wed, 24 Jul 2024 04:00:17 -0400 spectro https://spypharm.com/unaids-boss-calls-on-gilead-to-provide-miracle-drug-to-developing-countries https://spypharm.com/unaids-boss-calls-on-gilead-to-provide-miracle-drug-to-developing-countries Wed, 24 Jul 2024 04:00:17 -0400 spectro https://spypharm.com/telix-raises-398m-to-advance-kidney-and-brain-cancer-radiotherapies https://spypharm.com/telix-raises-398m-to-advance-kidney-and-brain-cancer-radiotherapies Wed, 24 Jul 2024 04:00:17 -0400 spectro https://spypharm.com/podcast-5-doing-digital-deals-in-life-sciences-deal-structure-terms-and-series-conclusions https://spypharm.com/podcast-5-doing-digital-deals-in-life-sciences-deal-structure-terms-and-series-conclusions Wed, 24 Jul 2024 04:00:17 -0400 spectro https://spypharm.com/jj-drops-addexs-epilepsy-treatment-after-flunking-in-phase-ii https://spypharm.com/jj-drops-addexs-epilepsy-treatment-after-flunking-in-phase-ii Wed, 24 Jul 2024 04:00:16 -0400 spectro https://spypharm.com/fda-accepts-mesoblasts-latest-bla-for-paediatric-gvhd-cell-therapy https://spypharm.com/fda-accepts-mesoblasts-latest-bla-for-paediatric-gvhd-cell-therapy Wed, 24 Jul 2024 04:00:16 -0400 spectro https://spypharm.com/hhs-gives-thumbs-down-to-bluebirds-fertility-support-programme https://spypharm.com/hhs-gives-thumbs-down-to-bluebirds-fertility-support-programme Wed, 24 Jul 2024 04:00:16 -0400 spectro https://spypharm.com/oscotec-sees-highest-patent-filings-and-grants-during-june-in-q2-2024 https://spypharm.com/oscotec-sees-highest-patent-filings-and-grants-during-june-in-q2-2024 Mon, 22 Jul 2024 04:00:16 -0400 spectro https://spypharm.com/dechra-pharmaceuticals-sees-highest-patent-filings-and-grants-during-may-in-q2-2024 https://spypharm.com/dechra-pharmaceuticals-sees-highest-patent-filings-and-grants-during-may-in-q2-2024 Mon, 22 Jul 2024 04:00:15 -0400 spectro https://spypharm.com/oramed-pharmaceuticals-sees-highest-patent-filings-and-grants-during-april-in-q2-2024 https://spypharm.com/oramed-pharmaceuticals-sees-highest-patent-filings-and-grants-during-april-in-q2-2024 Mon, 22 Jul 2024 04:00:15 -0400 spectro https://spypharm.com/orion-sees-highest-patent-filings-and-grants-during-may-in-q2-2024 https://spypharm.com/orion-sees-highest-patent-filings-and-grants-during-may-in-q2-2024 Mon, 22 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/y-mabs-therapeutics-sees-highest-patent-filings-and-grants-during-june-in-q2-2024 https://spypharm.com/y-mabs-therapeutics-sees-highest-patent-filings-and-grants-during-june-in-q2-2024 Mon, 22 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/kiniksa-pharmaceuticals-sees-highest-patent-filings-and-grants-during-april-in-q2-2024 https://spypharm.com/kiniksa-pharmaceuticals-sees-highest-patent-filings-and-grants-during-april-in-q2-2024 Mon, 22 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/medicover-sees-highest-patent-filings-and-grants-during-may-in-q2-2024 https://spypharm.com/medicover-sees-highest-patent-filings-and-grants-during-may-in-q2-2024 Mon, 22 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/iteos-therapeutics-sees-highest-patent-filings-and-grants-during-may-in-q2-2024 https://spypharm.com/iteos-therapeutics-sees-highest-patent-filings-and-grants-during-may-in-q2-2024 Mon, 22 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/rusan-pharmas-api-plant-in-ankleshwar-receives-usfda-gmp-approval https://spypharm.com/rusan-pharmas-api-plant-in-ankleshwar-receives-usfda-gmp-approval Mon, 22 Jul 2024 04:00:10 -0400 spectro https://spypharm.com/certara-sees-highest-patent-filings-and-grants-during-june-in-q2-2024 https://spypharm.com/certara-sees-highest-patent-filings-and-grants-during-june-in-q2-2024 Mon, 22 Jul 2024 04:00:10 -0400 spectro https://spypharm.com/fda-launches-new-rare-disease-innovation-hub https://spypharm.com/fda-launches-new-rare-disease-innovation-hub Sat, 20 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/boehringer-ingelheim-offers-humira-biosimilar-at-92-discount https://spypharm.com/boehringer-ingelheim-offers-humira-biosimilar-at-92-discount Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/seventh-patient-cured-of-hiv-among-highlights-at-aids-2024 https://spypharm.com/seventh-patient-cured-of-hiv-among-highlights-at-aids-2024 Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/rona-therapeutics-gains-series-a-funds-for-sirna-pipeline-expansion https://spypharm.com/rona-therapeutics-gains-series-a-funds-for-sirna-pipeline-expansion Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/meitheal-gains-rights-to-contepo-from-nabriva-in-north-america https://spypharm.com/meitheal-gains-rights-to-contepo-from-nabriva-in-north-america Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/ema-accepts-decipheras-maa-cell-tumour-treatment-for-review https://spypharm.com/ema-accepts-decipheras-maa-cell-tumour-treatment-for-review Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/bms-gains-ema-validation-for-opdivoyervoy-combo-in-liver-cancer https://spypharm.com/bms-gains-ema-validation-for-opdivoyervoy-combo-in-liver-cancer Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/tech-leaders-125m-boosts-parker-institutes-immunotherapy-research https://spypharm.com/tech-leaders-125m-boosts-parker-institutes-immunotherapy-research Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/exscientia-acquires-oral-cdk7-inhibitor-for-20m-plans-breast-cancer-trial https://spypharm.com/exscientia-acquires-oral-cdk7-inhibitor-for-20m-plans-breast-cancer-trial Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/ardelyx-sues-cms-over-revamped-kidney-disease-drug-payment-bundle https://spypharm.com/ardelyx-sues-cms-over-revamped-kidney-disease-drug-payment-bundle Sat, 20 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/scorpion-therapeutics-secures-150m-for-oncology-pipeline https://spypharm.com/scorpion-therapeutics-secures-150m-for-oncology-pipeline Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/china-nmpa-approves-zai-lab-argenxs-efgartigimod-alfa-for-gmg https://spypharm.com/china-nmpa-approves-zai-lab-argenxs-efgartigimod-alfa-for-gmg Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/fda-issues-crl-to-orexos-nda-for-opioid-overdose-medication https://spypharm.com/fda-issues-crl-to-orexos-nda-for-opioid-overdose-medication Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/gene-therapy-how-the-cro-of-veristat-cut-trial-database-costs-by-30 https://spypharm.com/gene-therapy-how-the-cro-of-veristat-cut-trial-database-costs-by-30 Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/finding-the-right-solution-and-partner-for-your-drug-products-commercial-supply-chain https://spypharm.com/finding-the-right-solution-and-partner-for-your-drug-products-commercial-supply-chain Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/abbvies-humira-loss-of-exclusivity-has-been-a-missed-opportunity-for-competitors https://spypharm.com/abbvies-humira-loss-of-exclusivity-has-been-a-missed-opportunity-for-competitors Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/catalym-secures-150m-to-advance-gdf-15-targeting-immune-modulator https://spypharm.com/catalym-secures-150m-to-advance-gdf-15-targeting-immune-modulator Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/cardurion-closes-260m-in-series-b-to-develop-cardiovascular-pipeline https://spypharm.com/cardurion-closes-260m-in-series-b-to-develop-cardiovascular-pipeline Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/the-us-biosecure-act-threatens-to-destabilise-the-pharmaceutical-industry https://spypharm.com/the-us-biosecure-act-threatens-to-destabilise-the-pharmaceutical-industry Thu, 18 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/fda-priority-review-advances-ataras-tabelecleucel-for-viral-infection https://spypharm.com/fda-priority-review-advances-ataras-tabelecleucel-for-viral-infection Thu, 18 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/astrazenecas-tagrisso-gains-approval-in-canada-for-nsclc https://spypharm.com/astrazenecas-tagrisso-gains-approval-in-canada-for-nsclc Tue, 16 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/delix-plans-further-trials-with-neuroplastogen-after-positive-phase-i-data https://spypharm.com/delix-plans-further-trials-with-neuroplastogen-after-positive-phase-i-data Tue, 16 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/abbvie-looks-to-add-an-eighth-indication-for-jak-inhibitor-rinvoq https://spypharm.com/abbvie-looks-to-add-an-eighth-indication-for-jak-inhibitor-rinvoq Tue, 16 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/nona-biosciences-partners-with-alayabio-for-car-t-therapy https://spypharm.com/nona-biosciences-partners-with-alayabio-for-car-t-therapy Tue, 16 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/ausperbio-secures-funding-to-advance-ahb-137-for-chb https://spypharm.com/ausperbio-secures-funding-to-advance-ahb-137-for-chb Tue, 16 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/mabwells-9mw2821-gains-fda-fast-track-status-for-breast-cancer https://spypharm.com/mabwells-9mw2821-gains-fda-fast-track-status-for-breast-cancer Tue, 16 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/conflict-means-millions-of-children-are-missing-vaccinations-un-says https://spypharm.com/conflict-means-millions-of-children-are-missing-vaccinations-un-says Tue, 16 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/exploring-melbournes-booming-life-sciences-sector https://spypharm.com/exploring-melbournes-booming-life-sciences-sector Tue, 16 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/explainer-labour-has-been-elected-in-the-uk-now-what https://spypharm.com/explainer-labour-has-been-elected-in-the-uk-now-what Sun, 14 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/nhs-rolls-out-more-convenient-ocrevus-injection-for-multiple-sclerosis https://spypharm.com/nhs-rolls-out-more-convenient-ocrevus-injection-for-multiple-sclerosis Sun, 14 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/ipsen-gains-global-rights-to-foreseen-biotechs-fs001-adc https://spypharm.com/ipsen-gains-global-rights-to-foreseen-biotechs-fs001-adc Sun, 14 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/fda-grants-fast-track-designation-to-askbios-ab-1005-for-pd https://spypharm.com/fda-grants-fast-track-designation-to-askbios-ab-1005-for-pd Sun, 14 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/pan-cancer-t-raises-funds-through-seed-extension-round https://spypharm.com/pan-cancer-t-raises-funds-through-seed-extension-round Sun, 14 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/msd-closes-13bn-eyebio-acquisition-plans-pivotal-trial-for-lead-asset https://spypharm.com/msd-closes-13bn-eyebio-acquisition-plans-pivotal-trial-for-lead-asset Sun, 14 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/crossject-secures-funding-from-french-government-for-needle-free-platform https://spypharm.com/crossject-secures-funding-from-french-government-for-needle-free-platform Sun, 14 Jul 2024 04:00:06 -0400 spectro https://spypharm.com/ausperbio-ahb-137-gains-breakthrough-status-in-china-for-chb https://spypharm.com/ausperbio-ahb-137-gains-breakthrough-status-in-china-for-chb Fri, 12 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/biotech-survey-highlights-where-industry-can-focus-for-a-thriving-future https://spypharm.com/biotech-survey-highlights-where-industry-can-focus-for-a-thriving-future Fri, 12 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/hong-kong-approves-leqembi-for-alzheimers-treatment https://spypharm.com/hong-kong-approves-leqembi-for-alzheimers-treatment Fri, 12 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/rgenta-therapeutics-rgt-61159-gains-ind-approval-to-treat-cancers https://spypharm.com/rgenta-therapeutics-rgt-61159-gains-ind-approval-to-treat-cancers Fri, 12 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/barda-and-tiba-biotech-link-to-develop-flu-therapeutics https://spypharm.com/barda-and-tiba-biotech-link-to-develop-flu-therapeutics Fri, 12 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/boehringer-ingelheim-plans-sustainability-work-for-the-long-term https://spypharm.com/boehringer-ingelheim-plans-sustainability-work-for-the-long-term Fri, 12 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/jj-asserts-its-place-in-atopic-dermatitis-space-with-yellow-jersey-acquisition https://spypharm.com/jj-asserts-its-place-in-atopic-dermatitis-space-with-yellow-jersey-acquisition Fri, 12 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/merz-wins-185m-bid-for-bankrupt-acorda-assets-and-increases-us-workforce-by-50 https://spypharm.com/merz-wins-185m-bid-for-bankrupt-acorda-assets-and-increases-us-workforce-by-50 Fri, 12 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/aspect-wins-7275m-from-canadian-government-for-bioprinted-pipeline https://spypharm.com/aspect-wins-7275m-from-canadian-government-for-bioprinted-pipeline Fri, 12 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/after-adcom-rejection-fda-rebuffs-novo-nordisks-once-weekly-insulin https://spypharm.com/after-adcom-rejection-fda-rebuffs-novo-nordisks-once-weekly-insulin Fri, 12 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/chinas-nmpa-approves-antengenes-xpovio-for-dlbcl https://spypharm.com/chinas-nmpa-approves-antengenes-xpovio-for-dlbcl Wed, 10 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/uk-pharma-group-reprimands-novo-nordisk-for-undisclosed-payments https://spypharm.com/uk-pharma-group-reprimands-novo-nordisk-for-undisclosed-payments Wed, 10 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/ionctura-expands-pi3k-inhibitor-programme-to-nsclc https://spypharm.com/ionctura-expands-pi3k-inhibitor-programme-to-nsclc Wed, 10 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/scirhom-secures-70m-for-autoimmune-diseases-treatments https://spypharm.com/scirhom-secures-70m-for-autoimmune-diseases-treatments Wed, 10 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/taiho-exercises-option-for-arcus-biosciences-quemliclustat-in-asia https://spypharm.com/taiho-exercises-option-for-arcus-biosciences-quemliclustat-in-asia Wed, 10 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/ligand-pharmaceuticals-to-acquire-apeiron-biologics-for-100m https://spypharm.com/ligand-pharmaceuticals-to-acquire-apeiron-biologics-for-100m Wed, 10 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/moderna-and-mitsubishi-tanabe-link-on-mrna-vaccines-in-japan https://spypharm.com/moderna-and-mitsubishi-tanabe-link-on-mrna-vaccines-in-japan Wed, 10 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/iteos-and-gsk-hit-enrolment-milestone-with-phase-iii-tigit-lung-cancer-trial https://spypharm.com/iteos-and-gsk-hit-enrolment-milestone-with-phase-iii-tigit-lung-cancer-trial Wed, 10 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/roche-relaunches-refillable-wet-amd-implant-two-years-after-recall https://spypharm.com/roche-relaunches-refillable-wet-amd-implant-two-years-after-recall Wed, 10 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/lilly-bolsters-ibd-portfolio-with-32bn-morphic-acquisition https://spypharm.com/lilly-bolsters-ibd-portfolio-with-32bn-morphic-acquisition Wed, 10 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/dalfampridine-ir-by-solaxa-for-spinocerebellar-ataxia-sca-likelihood-of-approval https://spypharm.com/dalfampridine-ir-by-solaxa-for-spinocerebellar-ataxia-sca-likelihood-of-approval Sat, 06 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/ctx-310-by-crispr-therapeutics-for-hypertriglyceridemia-likelihood-of-approval https://spypharm.com/ctx-310-by-crispr-therapeutics-for-hypertriglyceridemia-likelihood-of-approval Sat, 06 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/bnt-325-by-duality-biologics-shanghai-for-metastatic-ovarian-cancer-likelihood-of-approval https://spypharm.com/bnt-325-by-duality-biologics-shanghai-for-metastatic-ovarian-cancer-likelihood-of-approval Sat, 06 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/azd-2389-by-astrazeneca-for-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval https://spypharm.com/azd-2389-by-astrazeneca-for-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval Sat, 06 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/nn-6561-by-novo-nordisk-for-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval https://spypharm.com/nn-6561-by-novo-nordisk-for-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval Sat, 06 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/ctx-310-by-crispr-therapeutics-for-heterozygous-familial-hypercholesterolemia-hefh-likelihood-of-approval https://spypharm.com/ctx-310-by-crispr-therapeutics-for-heterozygous-familial-hypercholesterolemia-hefh-likelihood-of-approval Sat, 06 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/ctx-310-by-crispr-therapeutics-for-homozygous-familial-hypercholesterolemia-hofh-likelihood-of-approval https://spypharm.com/ctx-310-by-crispr-therapeutics-for-homozygous-familial-hypercholesterolemia-hofh-likelihood-of-approval Sat, 06 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/can-3110-by-candel-therapeutics-for-high-grade-glioma-likelihood-of-approval https://spypharm.com/can-3110-by-candel-therapeutics-for-high-grade-glioma-likelihood-of-approval Sat, 06 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/lp-184-by-starlight-therapeutics-for-non-small-cell-lung-cancer-likelihood-of-approval https://spypharm.com/lp-184-by-starlight-therapeutics-for-non-small-cell-lung-cancer-likelihood-of-approval Sat, 06 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/ictcar-028-by-innovative-cellular-therapeutics-for-hematological-tumor-likelihood-of-approval https://spypharm.com/ictcar-028-by-innovative-cellular-therapeutics-for-hematological-tumor-likelihood-of-approval Sat, 06 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/johnson-johnson-gains-fda-and-ec-approvals-for-tb-treatment https://spypharm.com/johnson-johnson-gains-fda-and-ec-approvals-for-tb-treatment Thu, 04 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/modernas-mrna-influenza-vaccine-receives-176m-boost https://spypharm.com/modernas-mrna-influenza-vaccine-receives-176m-boost Thu, 04 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/left-in-limbo-when-pharma-halts-rare-disease-research https://spypharm.com/left-in-limbo-when-pharma-halts-rare-disease-research Thu, 04 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/eli-lillys-donanemab-wins-fda-approval-for-alzheimers-disease https://spypharm.com/eli-lillys-donanemab-wins-fda-approval-for-alzheimers-disease Thu, 04 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/ema-approves-sanofis-dupixent-for-copd-treatment-in-adults https://spypharm.com/ema-approves-sanofis-dupixent-for-copd-treatment-in-adults Thu, 04 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/gsk-and-curevac-restructure-mrna-vaccine-development-deal https://spypharm.com/gsk-and-curevac-restructure-mrna-vaccine-development-deal Thu, 04 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/beacon-secures-170m-to-advance-ophthalmic-gene-therapies https://spypharm.com/beacon-secures-170m-to-advance-ophthalmic-gene-therapies Thu, 04 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/biogen-completes-115bn-hi-bio-acquisition-to-expand-immunology-presence https://spypharm.com/biogen-completes-115bn-hi-bio-acquisition-to-expand-immunology-presence Thu, 04 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/emergent-scores-us-medical-countermeasure-contracts-worth-over-250m https://spypharm.com/emergent-scores-us-medical-countermeasure-contracts-worth-over-250m Thu, 04 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/protecting-your-drug-products-strategies-for-preventing-metal-contamination-in-powders https://spypharm.com/protecting-your-drug-products-strategies-for-preventing-metal-contamination-in-powders Thu, 04 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-idrebormilast https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-idrebormilast Tue, 02 Jul 2024 04:00:15 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pmv-pharmaceuticalss-rezatapopt https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pmv-pharmaceuticalss-rezatapopt Tue, 02 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-osivelotor https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-osivelotor Tue, 02 Jul 2024 04:00:14 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-vertex-pharmaceuticalss-suzetrigine https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-vertex-pharmaceuticalss-suzetrigine Tue, 02 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-atirmociclib https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-atirmociclib Tue, 02 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-atai-life-sciencess-rl-007 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-atai-life-sciencess-rl-007 Tue, 02 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-crispr-therapeuticss-ctx-112 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-crispr-therapeuticss-ctx-112 Tue, 02 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-influenza-quadrivalent-vaccine https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-influenza-quadrivalent-vaccine Tue, 02 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-spur-therapeuticss-flt-201 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-spur-therapeuticss-flt-201 Tue, 02 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-pf-07264660 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-pf-07264660 Tue, 02 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/amylyx-ventures-into-metabolic-diseases-market-with-351m-deal https://spypharm.com/amylyx-ventures-into-metabolic-diseases-market-with-351m-deal Sun, 30 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/coherus-offloads-humira-biosimilar-yusimry-for-40m https://spypharm.com/coherus-offloads-humira-biosimilar-yusimry-for-40m Sun, 30 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/can-routinely-collected-primary-care-data-drive-life-sciences-investment-in-the-uk https://spypharm.com/can-routinely-collected-primary-care-data-drive-life-sciences-investment-in-the-uk Sun, 30 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/embracing-digital-solutions-for-enhanced-patient-care https://spypharm.com/embracing-digital-solutions-for-enhanced-patient-care Sun, 30 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/from-data-to-action-igniting-the-healthcare-revolution https://spypharm.com/from-data-to-action-igniting-the-healthcare-revolution Sun, 30 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/alumis-raises-250m-in-ipo-as-biotech-stock-stirs https://spypharm.com/alumis-raises-250m-in-ipo-as-biotech-stock-stirs Sun, 30 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/holoclara-gains-series-a-financing-for-worm-derived-therapies https://spypharm.com/holoclara-gains-series-a-financing-for-worm-derived-therapies Sun, 30 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/eisai-and-biogen-launch-leqembi-for-alzheimers-in-china https://spypharm.com/eisai-and-biogen-launch-leqembi-for-alzheimers-in-china Sun, 30 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/supreme-court-votes-against-purdue-pharmas-opioid-settlement https://spypharm.com/supreme-court-votes-against-purdue-pharmas-opioid-settlement Sun, 30 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/us-justice-dept-cracks-down-on-healthcare-fraud-schemes-linked-to-275bn-loss https://spypharm.com/us-justice-dept-cracks-down-on-healthcare-fraud-schemes-linked-to-275bn-loss Sun, 30 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/novo-nordisks-ocedurenone-phase-iii-flop-costs-company-816m https://spypharm.com/novo-nordisks-ocedurenone-phase-iii-flop-costs-company-816m Fri, 28 Jun 2024 04:00:13 -0400 spectro https://spypharm.com/fda-issues-complete-response-to-daiichi-sankyo-msds-bla-for-nsclc https://spypharm.com/fda-issues-complete-response-to-daiichi-sankyo-msds-bla-for-nsclc Fri, 28 Jun 2024 04:00:13 -0400 spectro https://spypharm.com/abbvie-gains-fda-approval-for-epkinly-in-follicular-lymphoma https://spypharm.com/abbvie-gains-fda-approval-for-epkinly-in-follicular-lymphoma Fri, 28 Jun 2024 04:00:13 -0400 spectro https://spypharm.com/formation-bio-secures-372m-funds-for-ai-driven-drug-platform https://spypharm.com/formation-bio-secures-372m-funds-for-ai-driven-drug-platform Fri, 28 Jun 2024 04:00:12 -0400 spectro https://spypharm.com/us-cdc-recommends-routine-rsv-vaccination-for-older-adults https://spypharm.com/us-cdc-recommends-routine-rsv-vaccination-for-older-adults Fri, 28 Jun 2024 04:00:12 -0400 spectro https://spypharm.com/ai-and-stable-funding-environments-are-catalysts-for-biotech-assets https://spypharm.com/ai-and-stable-funding-environments-are-catalysts-for-biotech-assets Fri, 28 Jun 2024 04:00:12 -0400 spectro https://spypharm.com/2seventy-bio-completes-40m-haemophilia-a-program-deal-with-novo-nordisk https://spypharm.com/2seventy-bio-completes-40m-haemophilia-a-program-deal-with-novo-nordisk Fri, 28 Jun 2024 04:00:12 -0400 spectro https://spypharm.com/verona-scores-fda-approval-for-ohtuvayre-as-copd-maintenance-therapy https://spypharm.com/verona-scores-fda-approval-for-ohtuvayre-as-copd-maintenance-therapy Fri, 28 Jun 2024 04:00:12 -0400 spectro https://spypharm.com/biotech-fund-curiebio-augments-reserves-with-380m-to-boost-startups https://spypharm.com/biotech-fund-curiebio-augments-reserves-with-380m-to-boost-startups Fri, 28 Jun 2024 04:00:12 -0400 spectro https://spypharm.com/fda-go-ahead-for-verona-ohtuvayre-transforms-us-copd-exacerbator-market https://spypharm.com/fda-go-ahead-for-verona-ohtuvayre-transforms-us-copd-exacerbator-market Fri, 28 Jun 2024 04:00:12 -0400 spectro https://spypharm.com/novavax-seeks-ema-approval-for-updated-jn1-covid-19-vaccine https://spypharm.com/novavax-seeks-ema-approval-for-updated-jn1-covid-19-vaccine Wed, 26 Jun 2024 04:00:15 -0400 spectro https://spypharm.com/gsks-omjjara-gains-approval-in-japan-for-myelofibrosis-treatment https://spypharm.com/gsks-omjjara-gains-approval-in-japan-for-myelofibrosis-treatment Wed, 26 Jun 2024 04:00:15 -0400 spectro https://spypharm.com/novo-nordisk-invests-41bn-in-manufacturing-facility-in-nc https://spypharm.com/novo-nordisk-invests-41bn-in-manufacturing-facility-in-nc Wed, 26 Jun 2024 04:00:15 -0400 spectro https://spypharm.com/ethris-shares-positive-data-with-mrna-drug-following-new-funding https://spypharm.com/ethris-shares-positive-data-with-mrna-drug-following-new-funding Wed, 26 Jun 2024 04:00:15 -0400 spectro https://spypharm.com/merck-kgaa-abandons-phase-iii-trial-for-108bn-head-neck-cancer-drug https://spypharm.com/merck-kgaa-abandons-phase-iii-trial-for-108bn-head-neck-cancer-drug Wed, 26 Jun 2024 04:00:15 -0400 spectro https://spypharm.com/oncoinvents-radspherin-has-fda-fast-track-status-for-ovarian-cancer https://spypharm.com/oncoinvents-radspherin-has-fda-fast-track-status-for-ovarian-cancer Wed, 26 Jun 2024 04:00:15 -0400 spectro https://spypharm.com/pharma-packaging-solutions-design-and-companies https://spypharm.com/pharma-packaging-solutions-design-and-companies Wed, 26 Jun 2024 04:00:14 -0400 spectro https://spypharm.com/pharma-ma-the-top-high-value-deals-in-2023 https://spypharm.com/pharma-ma-the-top-high-value-deals-in-2023 Wed, 26 Jun 2024 04:00:13 -0400 spectro https://spypharm.com/magazine-uks-new-netflix-style-funding-model-for-antibiotics-goeslive https://spypharm.com/magazine-uks-new-netflix-style-funding-model-for-antibiotics-goeslive Wed, 26 Jun 2024 04:00:13 -0400 spectro https://spypharm.com/medical-packaging-companies-in-pharmaceutical-contract-manufacturing https://spypharm.com/medical-packaging-companies-in-pharmaceutical-contract-manufacturing Wed, 26 Jun 2024 04:00:13 -0400 spectro https://spypharm.com/sanofi-and-biovac-partner-to-produce-polio-vaccines-in-africa https://spypharm.com/sanofi-and-biovac-partner-to-produce-polio-vaccines-in-africa Sat, 22 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/astrazenecas-truqap-and-faslodex-combo-receives-approval-in-eu https://spypharm.com/astrazenecas-truqap-and-faslodex-combo-receives-approval-in-eu Sat, 22 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/will-whos-new-guidance-spur-hepatitis-b-immunisation https://spypharm.com/will-whos-new-guidance-spur-hepatitis-b-immunisation Sat, 22 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/sareptas-elevidys-secures-us-label-expansion-for-dmd https://spypharm.com/sareptas-elevidys-secures-us-label-expansion-for-dmd Sat, 22 Jun 2024 04:00:05 -0400 spectro https://spypharm.com/emergent-to-sell-us-sterile-manufacturing-facility-to-bora https://spypharm.com/emergent-to-sell-us-sterile-manufacturing-facility-to-bora Sat, 22 Jun 2024 04:00:05 -0400 spectro https://spypharm.com/johnson-johnson-seeks-fda-approval-for-tremfya-for-crohns-disease https://spypharm.com/johnson-johnson-seeks-fda-approval-for-tremfya-for-crohns-disease Sat, 22 Jun 2024 04:00:05 -0400 spectro https://spypharm.com/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments https://spypharm.com/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments Sat, 22 Jun 2024 04:00:05 -0400 spectro